Navigation Links
Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
Date:11/12/2012

uture events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our intention to develop and commercialize a proprietary beta-lactase enzyme product candidate using the acquired assets that will have the desired results, our intention to commence a Phase II clinical trial and to obtain FDA approval of an IND and/or BLA for the new product candidate and the expected size of the market for C. diff therapeutics. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, our inability to timely commence or complete the clinical trials consistent with our current expectations, our inability to successfully develop, receive regulatory approvals for or to commercialize a new product candidate to treat C. diff infection, the failure of clinical results for SYN-004 to support the results obtained for P1A or achieve desired results and other factors described in Synthetic Biologics' report on Form 10-K/A for the year ended December 31, 2011 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

[1] GlobalData. Beta-lactam Antibiotics Sales - Uni
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Taming mavericks: Stanford researchers use synthetic magnetism to control light
2. Synthetic Biologics Completes $10.8 Million Private Placement Financing
3. Synthetic Biologics Announces $10.8 Million Financing
4. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
5. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
6. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
7. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
8. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
11. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 29, 2015 , ... Asymmetrex, LLC founder and ... the full range of capabilities of its unique cache of technologies for identifying, ... day-to-day renewal and repair of normal tissues and organs. This property makes them ...
(Date:7/28/2015)... ... 29, 2015 , ... Strong Animals™ announced today that research conducted by South ... at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL showed feed ... milk fat content. Also, feed containing Stay Strong™ for Dairy Cows took longer than ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... helped by hearing aids achieved significant and sometimes profound ... hybrid cochlear implant devices, according to a new multicenter ... In the study, described online ahead of ... 10 medical centers and private clinics in ...
(Date:7/28/2015)... July 21, 2015 ... the addition of the "Analysis of the ... their offering. Globally, flow cytometry remains ... cell proliferation, cancer, and stem cells. But the ... primarily because of demand from underdeveloped nations to ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2
... BOSTON, Sept. 22 A vast coalition of New ... to push for Congress to approve a legislative pathway for biosimilars ... innovative products to be developed. , , ... said in a letter to all members of the New England ...
... September 22 Subsequent to the,announcement of the EU ... September,2009, the German surveillance lab in the state of ... Triffid, which,is unapproved in the EU. , ... Alert announcements,regarding the presence of FP967/CDC Triffid in food ...
... Angeles, London, New Delhi, Singapore and Washington DC (July ... issue of Medical Decision Making , a large-scale, ... hospital resources even with an extremely effective public health ... attack and initiating a response to it. The ...
Cached Biology Technology:Regional Biotech Association Urges Support for Biosimilars Bill in Congress 2Accredited Construct Specific PCR Test for Recently Detected Unapproved GM Flax/Linseed FP967/CDC Triffid Available Through Genetic ID 2Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... online registration to the IOF World Congress on Osteoporosis ... October 31, 2008. To benefit from lower ... . Special registration fees are available for participants from ... 2008 only on-site registration, at higher rates, will be ...
... (Nasdaq:,AWRE), a leading supplier of broadband technology and biometrics ... operating results,for the third quarter of 2008 on Thursday, ... Tzannes and CFO Rick Moberg will host the,earnings conference ... and can be accessed on the,Investor Relations page of ...
... ability to respond? Biodiversity in a Warmer World, published ... Science , illustrates that cross-disciplinary research fostered by ... this urgent debate. , As an extremely diverse region ... the most to lose as a result of global ...
Cached Biology News:Aware Announces Q3 2008 Earnings Conference Call 2Smithsonian perspective: Biodiversity in a warmer world 2
...
... monoclonal antibody recognizes 30% of ... It does not cross-react with ... rheumatoid factor nor with pooled F(Ab)2 ... in ELISA to detect rheumatoid factor. ...
...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Biology Products: